VRDN vs. RDNT, BTSG, SHC, OPCH, WGS, PRVA, HTFL, VCYT, CON, and SGRY
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), GeneDx (WGS), Privia Health Group (PRVA), Heartflow (HTFL), Veracyte (VCYT), Concentra Group Holdings Parent (CON), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs. Its Competitors
Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.
RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viridian Therapeutics presently has a consensus price target of $34.88, suggesting a potential upside of 44.05%. RadNet has a consensus price target of $76.80, suggesting a potential downside of 0.17%. Given Viridian Therapeutics' higher possible upside, equities analysts plainly believe Viridian Therapeutics is more favorable than RadNet.
RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.
77.9% of RadNet shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 5.6% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, RadNet had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 5 mentions for RadNet and 2 mentions for Viridian Therapeutics. RadNet's average media sentiment score of 1.28 beat Viridian Therapeutics' score of 0.70 indicating that RadNet is being referred to more favorably in the news media.
Viridian Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Summary
RadNet beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 10/17/2025 by MarketBeat.com Staff
